Search

Your search keyword '"substance withdrawal syndrome"' showing total 3 results
Start Over Descriptor "substance withdrawal syndrome" Region central america
3 results on '"substance withdrawal syndrome"'

1. New Opioids Study Findings Have Been Reported by Investigators at New York State Psychiatric Institute and Hospital [Sublingual Dexmedetomidine (Bxcl501) Reduces Opioid Withdrawal Symptoms: Findings From a Multi-site, Phase 1b/2, Randomized, ...].

Subjects
PSYCHIATRIC hospitals, DRUG withdrawal symptoms, DEXMEDETOMIDINE, SUBLINGUAL drug administration, EPWORTH Sleepiness Scale, PLANT-based diet, OPIOIDS
Abstract

Keywords: Clinical Trial Identifier NCT05706649 EN Clinical Trial Identifier NCT05706649 2023 FEB 13 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Staff editors report on the newly launched clinical trial, NCT05706649, which has the following summary description: "This research aims to develop a better understanding and clinical knowledge of the effects of a plant-based diet on postprandial sleepiness.". [Extracted from the article]

Published
2023

2. Effect of Plant-based Diet on Postprandial Sleepiness.

Subjects
PLANT-based diet, DRUG withdrawal symptoms, DROWSINESS, MEDICAL research, ORTHOSTATIC hypotension
Abstract

Keywords: New York City; State:New York; United States; North and Central America; Cardiovascular Diseases and Conditions; Clinical Research; Clinical Trials and Studies; Diseases and Conditions; Drugs and Therapies; Health and Medicine; Hypotension; Opioids; Substance Withdrawal Syndrome EN New York City State:New York United States North and Central America Cardiovascular Diseases and Conditions Clinical Research Clinical Trials and Studies Diseases and Conditions Drugs and Therapies Health and Medicine Hypotension Opioids Substance Withdrawal Syndrome 2023 FEB 13 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Fresh data on Opioids are presented in a new report. For more information on this research see: Sublingual Dexmedetomidine (Bxcl501) Reduces Opioid Withdrawal Symptoms: Findings From a Multi-site, Phase 1b/2, Randomized, Double-blind, Placebo-controlled Trial. Clinical Trial Identifier NCT05706649, New York City, State:New York, United States, North and Central America, Cardiovascular Diseases and Conditions, Clinical Research, Clinical Trials and Studies, Diseases and Conditions, Drugs and Therapies, Health and Medicine, Hypotension, Opioids, Substance Withdrawal Syndrome. [Extracted from the article]

Published
2023

3. Drugs, drug dependance and the concept of plasticity.

Author

Edwards G

Subjects
Alcohol Drinking, Central America, Cross-Cultural Comparison, Drug and Narcotic Control, Ethnicity, France, Humans, Jews, Models, Psychological, Personality, Social Behavior, South America, Substance Withdrawal Syndrome, United Kingdom, Alcoholism, Behavior, Culture, Substance-Related Disorders
Published
1974

Catalog

Books, media, physical & digital resources
See catalog results